These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 29024725)

  • 1. Glucagon, a key factor in the pathophysiology of type 2 diabetes.
    Girard J
    Biochimie; 2017 Dec; 143():33-36. PubMed ID: 29024725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatostatin receptor subtype-2-deficient mice with diet-induced obesity have hyperglycemia, nonfasting hyperglucagonemia, and decreased hepatic glycogen deposition.
    Singh V; Grötzinger C; Nowak KW; Zacharias S; Göncz E; Pless G; Sauer IM; Eichhorn I; Pfeiffer-Guglielmi B; Hamprecht B; Wiedenmann B; Plöckinger U; Strowski MZ
    Endocrinology; 2007 Aug; 148(8):3887-99. PubMed ID: 17525126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The constitutive activation of Egr-1/C/EBPa mediates the development of type 2 diabetes mellitus by enhancing hepatic gluconeogenesis.
    Shen N; Jiang S; Lu JM; Yu X; Lai SS; Zhang JZ; Zhang JL; Tao WW; Wang XX; Xu N; Xue B; Li CJ
    Am J Pathol; 2015 Feb; 185(2):513-23. PubMed ID: 25438063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of dysregulated glucagon secretion in type 2 diabetes.
    D'Alessio D
    Diabetes Obes Metab; 2011 Oct; 13 Suppl 1():126-32. PubMed ID: 21824266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The role of glucagon in hyperglycemia. A review (author's transl)].
    Luyckx A
    Diabete Metab; 1975 Sep; 1(3):201-8. PubMed ID: 791728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On the role of the gut in diabetic hyperglucagonaemia.
    Lund A
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucose regulation in non-insulin-dependent diabetes mellitus. Interaction between pancreatic islets and the liver.
    Halter JB; Ward WK; Porte D; Best JD; Pfeifer MA
    Am J Med; 1985 Aug; 79(2B):6-12. PubMed ID: 2863979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Liver-α-Cell Axis and Type 2 Diabetes.
    Wewer Albrechtsen NJ; Pedersen J; Galsgaard KD; Winther-Sørensen M; Suppli MP; Janah L; Gromada J; Vilstrup H; Knop FK; Holst JJ
    Endocr Rev; 2019 Oct; 40(5):1353-1366. PubMed ID: 30920583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of glucagon in the pathogenesis of diabetes: the status of the controversy.
    Unger RH
    Metabolism; 1978 Nov; 27(11):1691-709. PubMed ID: 360007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disordered branched chain amino acid catabolism in pancreatic islets is associated with postprandial hypersecretion of glucagon in diabetic mice.
    Wada E; Kobayashi M; Kohno D; Kikuchi O; Suga T; Matsui S; Yokota-Hashimoto H; Honzawa N; Ikeuchi Y; Tsuneoka H; Hirano T; Obinata H; Sasaki T; Kitamura T
    J Nutr Biochem; 2021 Nov; 97():108811. PubMed ID: 34197915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experimental and clinical aspects of melatonin and clock genes in diabetes.
    Peschke E; Bähr I; Mühlbauer E
    J Pineal Res; 2015 Aug; 59(1):1-23. PubMed ID: 25904189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.
    Vilsbøll T; Knop FK; Krarup T; Johansen A; Madsbad S; Larsen S; Hansen T; Pedersen O; Holst JJ
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4897-903. PubMed ID: 14557471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon antagonism as a potential therapeutic target in type 2 diabetes.
    Bagger JI; Knop FK; Holst JJ; Vilsbøll T
    Diabetes Obes Metab; 2011 Nov; 13(11):965-71. PubMed ID: 21615669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenesis of fasting and postprandial hyperglycemia in type 2 diabetes: implications for therapy.
    Rizza RA
    Diabetes; 2010 Nov; 59(11):2697-707. PubMed ID: 20705776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of glucagon secretion.
    Young A
    Adv Pharmacol; 2005; 52():151-71. PubMed ID: 16492545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postprandial hyperglycemia in patients with noninsulin-dependent diabetes mellitus. Role of hepatic and extrahepatic tissues.
    Firth RG; Bell PM; Marsh HM; Hansen I; Rizza RA
    J Clin Invest; 1986 May; 77(5):1525-32. PubMed ID: 3517067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies on the mechanism of epinephrine-induced hyperglycemia in man. Evidence for participation of pancreatic glucagon secretion.
    Gerich JE; Lorenzi M; Tsalikian E; Karam JH
    Diabetes; 1976 Jan; 25(1):65-71. PubMed ID: 1107095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes.
    Cryer PE
    Endocrinology; 2012 Mar; 153(3):1039-48. PubMed ID: 22166985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Islet function and stress hyperglycemia: plasma glucose and epinephrine interaction.
    Halter JB; Beard JC; Porte D
    Am J Physiol; 1984 Jul; 247(1 Pt 1):E47-52. PubMed ID: 6377920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence That in Uncontrolled Diabetes, Hyperglucagonemia Is Required for Ketosis but Not for Increased Hepatic Glucose Production or Hyperglycemia.
    Meek TH; Dorfman MD; Matsen ME; Fischer JD; Cubelo A; Kumar MR; Taborsky GJ; Morton GJ
    Diabetes; 2015 Jul; 64(7):2376-87. PubMed ID: 25633417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.